Expert Content | Pfizer CentreOne

What to look for in a gene and cell therapy CDMO partner

Gene and cell therapies (GCTs) are offering life-changing new treatment options for genetic disorders. Our eBook examines the critical aspects of the development and manufacturing of GCTs and how we can help bring these therapeutics from clinical stages to commercialization.

What Makes Us Altogether Different

For over 40 years, we've been listening, solving, and guiding our partners' drug projects to success. But what makes us an altogether different kind of CDMO to work with? Find out here.

Using exact SI-ence to unlock the potential of your sterile injectable

Explore our infographic to discover how we navigate the intricate sterile injectable landscape to help deliver your high-quality therapeutics to patients who need them.

Making the complex. Simple.

Let our informative infographic explain exactly what makes us a leading CDMO — ready to meet your complex oral solid dose needs seamlessly and simply.

Harmonization in process development science

In this blog, Bernd Schümmelfeder, Director-Team Leader PPD Business Development at Pfizer, explores how process development — just like creating beautiful music — relies on collaboration between all involved.

Streamline your technology transfer

Outsourcing drug production to CDMO partners is becoming the norm across the pharmaceutical industry. But to succeed in the development, manufacture and scale-up of critical therapies, a robust approach to technology transfers is key to success.

Overcoming supply chain and logistics challenges with Pfizer CentreOne

Managing your pharmaceutical supply chain is a lot like following a good cake recipe. Both require thorough preparation, a comprehensive plan of action, and the best ingredients that come together to make something special - your drug product.

Sterile Injectables Supply on Demand

Demand for supplies of materials for sterile injectable production, such as glass vials, filters, and stoppers has soared, which has resulted in shortages that have impacted the manufacturing of other drug products.

De-risking API & Intermediate Supply in a Crisis

Pharmaceutical supply chains have been consistently growing in complexity for many years. For some products, their supply chains are so complex and globalized that they start in and return to Asia after circumnavigating the globe several times.

Highly Potent Oral Solids: Top Considerations

Understanding product classification and the heightened complexity of HPAPI drug substance transfer and manufacturing is critical. Developers are increasingly working with CDMOs to commercialize their HPAPIs.

Building More Resilient API Supply Chains

Safe, secure and reliable supply lines for key medicines is one of pharma's top priorities.

How to Secure a Sustainable Supply of Raw Materials

There are a few steps pharmaceutical companies can take to minimize insecurity in their supply chain even in a rapidly changing market, find out what these are in this article.

Insights & Resources